Information Provided By:
Fly News Breaks for January 22, 2018
NVO, LLY
Jan 22, 2018 | 06:29 EDT
Credit Suisse analyst Vamil Divan downgraded Eli Lilly (LLY) to Underperform from Neutral and cut his price target for the shares to $82 from $88. The analyst does not believe Lilly is on track to hit its mid-term guidance of 5% annual sales growth from 2015-2020. Divan notes he's $500M below consensus for Trulicity in 2021 based on market share gains for Novo Nordisk's (NVO) Victoza following its recent label expansion, the threat from Novo's once-weekly Ozempic and risk from upcoming Phase 3 data for Novo's oral semaglutide. Trulicity accounts for 40% of Lilly's sales growth from 2016-2021 based on current expectations, Divan tells investors in a research note partially titled "Diabetes Challenges Leave Sour Taste in Our Mouth"
News For LLY;NVO From the Last 2 Days
LLY
Mar 28, 2024 | 16:23 EDT
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here
LLY, NVO
Mar 26, 2024 | 07:08 EDT
JPMorgan estimates Amgen (AMGN) without its obesity pipeline is worth $240-$250 per share and that the market is assigning $30-$40 per share of value to Maritide. While the competitive bar for Maritide is high and moving higher based on Novo Nordisk's (NVO) recent pipeline updates, the obesity market is also "unprecedented in terms of size," the analyst tells investors in a research note. The firm estimates peak sales for Maritide of $6B, equating to mid-single-digit share within the incretin space. JPMorgan believes this supports a value roughly in-line with what is reflected in Amgen's current share price. It sees a positive risk/reward scenario given the recent pullback but maintains a Neutral rating on the name with a $290 price target. The firm says Amgen is viewed as the best positioned name beyond Eli Lilly (LLY) and Novo to have a role in the obesity space.